Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.

New findings could explain the link between chronic stress and reduced survival in women diagnosed with breast cancer, and could lead to new strategies to improve treatment outcomes.

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Researchers in the Vanderbilt Institute for Global Health are testing whether a unique “couples-centered” intervention developed in the southern African nation of Mozambique can reduce mother-to-child transmission of HIV.

On July 24 Vanderbilt scientist Eric Skaar, Ph.D., MPH, summarized his group’s latest paper in a tweet: “If S. aureus is going to drink our blood like a vampire, let's kill it with sunlight.”

Sara Van Driest, M.D., Ph.D., who is developing methods for precision dosing of pediatric medications at Vanderbilt University Medical Center (VUMC), has received a 2017 Clinical Scientist Development Award from the Doris Duke Charitable Foundation.